These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23894391)

  • 1. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.
    Pillay P; Ford N; Shubber Z; Ferrand RA
    PLoS One; 2013; 8(7):e68995. PubMed ID: 23894391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
    Takuva S; Evans D; Zuma K; Okello V; Louwagie G
    Pan Afr Med J; 2013; 15():5. PubMed ID: 23847702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
    Chendi BH; Okomo Assoumou MC; Jacobs GB; Yekwa EL; Lyonga E; Mesembe M; Eyoh A; Ikomey GM
    BMC Infect Dis; 2019 Feb; 19(1):194. PubMed ID: 30808298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.
    Mwesigire DM; Wu AW; Martin F; Katamba A; Seeley J
    BMC Health Serv Res; 2015 Jul; 15():292. PubMed ID: 26216221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.
    van Dijk JH; Sutcliffe CG; Hamangaba F; Bositis C; Watson DC; Moss WJ
    PLoS One; 2013; 8(1):e55111. PubMed ID: 23372824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies.
    Ayele TA; Worku A; Kebede Y; Alemu K; Kasim A; Shkedy Z
    Syst Rev; 2017 Aug; 6(1):173. PubMed ID: 28841912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.
    Shearer K; Brennan AT; Maskew M; Long L; Berhanu R; Sanne I; Fox MP
    J Int AIDS Soc; 2014; 17(1):19065. PubMed ID: 25361827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
    Teeranaipong P; Sirivichayakul S; Mekprasan S; Ohata PJ; Avihingsanon A; Ruxrungtham K; Putcharoen O
    PLoS One; 2016; 11(4):e0154221. PubMed ID: 27120449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
    Ngo-Giang-Huong N; Jourdain G; Amzal B; Sang-a-gad P; Lertkoonalak R; Eiamsirikit N; Tansuphasawasdikul S; Buranawanitchakorn Y; Yutthakasemsunt N; Mekviwattanawong S; McIntosh K; Lallemant M;
    PLoS One; 2011; 6(11):e27427. PubMed ID: 22132100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
    Bock P; Fatti G; Grimwood A
    Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
    Ramachandran G; Kumar AK; Ponnuraja C; Ramesh K; Rajesh L; Chandrasekharan C; Swaminathan S
    Indian J Med Res; 2013 Dec; 138(6):955-61. PubMed ID: 24521642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
    Cain LE; Phillips A; Lodi S; Sabin C; Bansi L; Justice A; Tate J; Logan R; Robins JM; Sterne JA; van Sighem A; de Wolf F; Bucher HC; Elzi L; Touloumi G; Vourli G; Esteve A; Casabona J; del Amo J; Moreno S; Seng R; Meyer L; Pérez-Hoyos S; Muga R; Abgrall S; Costagliola D; Hernán MA;
    AIDS; 2012 Aug; 26(13):1691-705. PubMed ID: 22546987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana.
    Shipton LK; Wester CW; Stock S; Ndwapi N; Gaolathe T; Thior I; Avalos A; Moffat HJ; Mboya JJ; Widenfelt E; Essex M; Hughes MD; Shapiro RL
    Int J Tuberc Lung Dis; 2009 Mar; 13(3):360-6. PubMed ID: 19275797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
    Keiser P; Nassar N; White C; Koen G; Moreno S
    HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
    PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.
    Manosuthi W; Sungkanuparph S; Vibhagool A; Rattanasiri S; Thakkinstian A
    HIV Med; 2004 Mar; 5(2):105-9. PubMed ID: 15012650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.